Revenues (Tables)

9 Months Ended

Sep. 30, 2024

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue by Product and by Geographic Area

Revenues were as follows (in millions):


	Three months ended September 30,
	2024						2023
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	683	$	362	$	1,045	$	673	$	313	$	986
ENBREL	817		8		825		1,026		9		1,035
XGEVA	373		168		541		374		145		519
Repatha	281		286		567		183		223		406
Otezla	460		104		564		462		105		567
TEPEZZA(1)	482		6		488		—		—		—
EVENITY	289		110		399		214		93		307
KYPROLIS	238		140		378		231		118		349
Nplate	345		111		456		322		97		419
Aranesp	105		232		337		107		216		323
KRYSTEXXA(1)	310		—		310		—		—		—
BLINCYTO	237		90		327		147		73		220
Vectibix	132		150		282		116		136		252
TEZSPIRE(2)	269		—		269		161		—		161
Other products(3)	958		405		1,363		675		329		1,004
Total product sales(4)	$	5,979	$	2,172	8,151		$	4,691	$	1,857	6,548
Other revenues					352						355
Total revenues					$	8,503					$	6,903
























	Nine months ended September 30,
	2024						2023
	U.S.		ROW		Total		U.S.		ROW		Total
Prolia	$	2,110	$	1,099	$	3,209	$	1,987	$	954	$	2,941
ENBREL	2,280		21		2,301		2,645		37		2,682
XGEVA	1,138		526		1,664		1,145		440		1,585
Repatha	824		792		1,616		592		626		1,218
Otezla	1,185		317		1,502		1,251		308		1,559
TEPEZZA(1)	1,379		12		1,391		—		—		—
EVENITY	806		326		1,132		570		272		842
KYPROLIS	712		419		1,131		699		354		1,053
Nplate	749		370		1,119		744		347		1,091
Aranesp	296		738		1,034		345		698		1,043
KRYSTEXXA(1)	839		—		839		—		—		—
BLINCYTO	555		280		835		418		202		620
Vectibix	385		414		799		345		388		733
TEZSPIRE(2)	676		—		676		390		—		390
Other products(3)	2,858		1,204		4,062		2,271		1,049		3,320
Total product sales(4)	$	16,792	$	6,518	23,310		$	13,402	$	5,675	19,077
Other revenues					1,028						917
Total revenues					$	24,338					$	19,994

_______

(1) TEPEZZA and KRYSTEXXA were acquired from the acquisition of Horizon on October 6, 2023, and include product sales in the periods after the acquisition date.

(2) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(3) Consists of product sales of our non-principal products.

(4) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2024 and 2023.